Taxane combined with lobaplatin or anthracycline for neoadjuvant chemotherapy of triple-negative breast cancer: a randomized, controlled, phase II study.

MLA

Wang, Cheng, et al. “Taxane Combined with Lobaplatin or Anthracycline for Neoadjuvant Chemotherapy of Triple-Negative Breast Cancer: A Randomized, Controlled, Phase II Study.” BMC Medicine, vol. 22, no. 1, June 2024, p. 252. EBSCOhost, https://doi.org/10.1186/s12916-024-03474-0.

APA

Wang, C., Yuan, L., Wu, X., Wang, Y., Tian, H., Zhang, G., Wan, A., Xiong, S., Wang, C., Zhou, Y., Ma, D., Bao, Y., Qu, M., Jiang, J., Zhang, Y., & Qi, X. (2024). Taxane combined with lobaplatin or anthracycline for neoadjuvant chemotherapy of triple-negative breast cancer: a randomized, controlled, phase II study. BMC Medicine, 22(1), 252. https://doi.org/10.1186/s12916-024-03474-0

Chicago

Wang, Cheng, Long Yuan, Xiujuan Wu, Yan Wang, Hao Tian, Guozhi Zhang, Andi Wan, et al. 2024. “Taxane Combined with Lobaplatin or Anthracycline for Neoadjuvant Chemotherapy of Triple-Negative Breast Cancer: A Randomized, Controlled, Phase II Study.” BMC Medicine 22 (1): 252. doi:10.1186/s12916-024-03474-0.